The U.S. Food and Drug Administration has unveiled a significant overhaul of its inspection approach for Contract Development and Manufacturing Organizations (CDMOs). The new framework, effective Q2 2026, moves from a calendar-based inspection cycle to a risk-stratified model that rewards facilities with strong compliance histories.
Under the updated system, CDMOs with no critical observations in the past three inspection cycles and robust data integrity programs can expect extended intervals between routine inspections. Conversely, facilities with repeat observations or significant deviations will face more frequent scrutiny.
Industry stakeholders have largely welcomed the change. This aligns inspection resources with actual risk, which is exactly what the industry has been advocating for. It incentivizes continuous improvement rather than just preparing for periodic inspections.
For B2B buyers evaluating CDMO partners, the FDA risk classification of facilities adds a new layer of due diligence data. Facilities classified in the lowest-risk tier effectively carry an implicit quality endorsement, which can streamline supplier qualification processes and reduce redundant auditing costs.